ClinicalTrials.gov
public full text
Public Domain
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
This study is being conducted to assess weight loss efficacy, as determined by changes in body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks accompanied by a lifestyle modification program in obese adolescents age 12-16 years.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pilot Testing a Novel Approach to Pediatric Obesity Treatment#442027
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)#373727
- A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity#912061
- Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.#866707
- Vyndaqel Capsules Special Investigation (ATTR-CM)#865431
Record · ID 1112194
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive